Please use this identifier to cite or link to this item: 10.1055/s-0038-1656542
Title: Clinical Characteristics and Outcomes of Patients with Lung Cancer and Venous Thromboembolism
Authors: RIETE Investigators
Ruiz-Artacho, Pedro
Trujillo-Santos, Javier
López-Jiménez, Luciano
Font, Carme
Díaz-Pedroche, María Del Carmen
Sánchez Muñoz-Torrero, Juan Francisco
Peris, Maria Luisa
Skride, Andris
Maestre, Ana
Monreal, Manuel
Keywords: 3.2 Clinical medicine;1.1. Scientific article indexed in Web of Science and/or Scopus database;SDG 3 - Good Health and Well-being
Issue Date: Apr-2018
Citation: RIETE Investigators , Ruiz-Artacho , P , Trujillo-Santos , J , López-Jiménez , L , Font , C , Díaz-Pedroche , M D C , Sánchez Muñoz-Torrero , J F , Peris , M L , Skride , A , Maestre , A & Monreal , M 2018 , ' Clinical Characteristics and Outcomes of Patients with Lung Cancer and Venous Thromboembolism ' , TH open : companion journal to thrombosis and haemostasis , vol. 2 , no. 2 , pp. e210-e217 . https://doi.org/10.1055/s-0038-1656542
Abstract: Background. The natural history of patients with lung cancer and venous thromboembolism (VTE) has not been consistently evaluated. Methods  We used the RIETE (Registro Informatizado Enfermedad TromboEmbólica) database to assess the clinical characteristics, time course, and outcomes during anticoagulation of lung cancer patients with acute, symptomatic VTE. Results  As of May 2017, a total of 1,725 patients were recruited: 1,208 (70%) presented with pulmonary embolism (PE) and 517 with deep vein thrombosis (DVT). Overall, 865 patients (50%) were diagnosed with cancer <3 months before, 1,270 (74%) had metastases, and 1,250 (72%) had no additional risk factors for VTE. During anticoagulation (median, 93 days), 166 patients had symptomatic VTE recurrences (recurrent DVT: 86, PE: 80), 63 had major bleeding (intracranial 11), and 870 died. The recurrence rate was twofold higher than the major bleeding rate during the first month, and over threefold higher beyond the first month. Fifty-seven patients died of PE and 15 died of bleeding. Most fatal PEs (84%) and most fatal bleeds (67%) occurred within the first month of therapy. Nine patients with fatal PE (16%) died within the first 24 hours. Of 72 patients dying of PE or bleeding, 15 (21%) had no metastases and 29 (40%) had the VTE shortly after surgery or immobility. Conclusion  Active surveillance on early signs and/or symptoms of VTE in patients with recently diagnosed lung cancer and prescription of prophylaxis in those undergoing surgery or during periods of immobilization might likely help prevent VTE better, detect it earlier, and treat it more efficiently.
DOI: 10.1055/s-0038-1656542
ISSN: 2512-9465
Appears in Collections:Research outputs from Pure / Zinātniskās darbības rezultāti no ZDIS Pure

Files in This Item:


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.